Ask AI
Optimizing Oral Targeted Therapies in HRpos HER2neg Breast Cancer

CE

Optimizing the Use of Targeted Therapies in Breast Cancer: Dosing, Toxicity Management, and Adherence

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 28, 2026

Expiration: January 27, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss the practical use of targeted therapies for hormone receptor (HR)–positive/HER2-negative breast cancer, including CDK4/6 inhibitors, PI3K/AKT pathway inhibitors, PARP inhibitors, and oral selective estrogen receptor degraders (SERDs). They review dosing considerations, adverse event (AE) monitoring and management, dose modification strategies, and pharmacist-led approaches to improving adherence, persistence, and patient outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions. 

How many people with breast cancer do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting:

A patient presents to your clinic to review her treatment plan (inavolisib plus palbociclib plus fulvestrant plus leuprolide). Based on safety data from the INAVO120 trial, which of the following AEs are most appropriate to review with the patient and her caregiver?

A patient with germline BRCA-mutated, HR-positive/HER2-negative early breast cancer is receiving adjuvant olaparib with ET. At follow-up, she reports persistent grade 2 nausea that is affecting daily activities and making it harder to stay on treatment. Which of the following is the best initial management strategy?

J.C. is a 56-year-old postmenopausal woman with pT2N1 HR-positive/HER2-negative early breast cancer. She completed AC-T and started letrozole plus adjuvant abemaciclib therapy 10 days ago. Her baseline labs are normal. Today she reports loose stools, 3-4/day above baseline, since Day 3; she is taking fluids but has not yet started an antidiarrheal. Complete blood count (CBC) today shows absolute neutrophil count (ANC) 1.1 × 10⁹/L, although she is afebrile and appears well.

J.C. is concerned about “being on this medication for 2 years if this diarrhea keeps happening.” Beyond antidiarrheal therapy, which pharmacist-led strategy is most likely to prevent treatment interruption?